(Q55877037)

14

object named as

P.C. Doherty

0 references

Julia L. Hurwitz

15

object named as

J.L. Hurwitz

0 references

author name string

S.A. Brown

2

0 references

A. Gutierrez

3

0 references

R. Sealy

4

0 references

W. Yue

5

0 references

B. Jones

6

0 references

T.D. Lockey

7

0 references

A. Zirkel

8

0 references

P. Freiden

9

0 references

B. Brown

10

0 references

S. Surman

11

0 references

C. Coleclough

12

0 references

K.S. Slobod

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

13

0 references

language of work or name

English

0 references

publication date

March 2005

0 references

published in

Vaccine

0 references

volume

23

0 references

issue

19

0 references

page(s)

2454-2464

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Vaccinia virus: a tool for research and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Oxidised mannan as a novel adjuvant inducing mucosal IgA production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Oxidised mannan-listeriolysin O conjugates induce Th1/Th2 cytokine responses after intranasal immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Requirement for cotolerogenic gene products in the clonal deletion of I-E reactive T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Clustering of Th Cell Epitopes on Exposed Regions of HIV Envelope Despite Defects in Antibody Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Development of a DNA-MVA/HIVA vaccine for Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Modulation of the antibody response to the HIV envelope subunit by co-administration of infectious or heat-inactivated canarypoxvirus (ALVAC) preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Duration of antiviral immunity after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Memory B-cell persistence is independent of persisting immunizing antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Maturation and dispersal of B-cell clones during T cell-dependent antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Microanatomy of lymphoid tissue during humoral immune responses: structure function relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Immunological memory: a function of antigen persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Patterns of isotype expression by B cell clones responding to thymus-dependent and thymus-independent antigens in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Predominate HIV1-specific IgG activity in various mucosal compartments of HIV1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Polyclonal antibodies to mannan from yeast also recognize the carbohydrate structure of gp120 of the AIDS virus: an approach to raise neutralizing antibodies to HIV-1 infection in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.030